Quantcast

Latest Pyrazines Stories

2011-07-05 07:01:14

(Ivanhoe Newswire) -- Smoking cigarettes is a dangerous habit that many are struggling to break, but for the smokers who choose to use one of the most popular smoking cessation drugs on the market, new warnings about the risk of serious cardiovascular events are on their way. A new study by researchers at Wake Forest Baptist Medical Center shows that the use of varenicline "“ marketed by Pfizer under the brand name Chantix "“ is associated with a 72 percent increased risk of...

5e6795178f868ce63381922f045eb730
2011-07-05 05:20:00

According to a new study described in the Canadian Medical Association Journal, healthy, middle-aged smokers who take the most popular smoking cessation drug on the market have a 72 percent increased risk of being hospitalized with a heart attack or other serious heart problem. "People want to quit smoking to reduce the risk of cardiovascular disease but in this case they're taking a drug that increases the risk for the very problems they're trying to avoid," Sonal Singh, M.D., M.P.H., an...

2011-06-07 07:00:00

SOUTH SAN FRANCISCO, Calif., June 7, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 16th Congress of the European Hematology Association (EHA) Annual Meeting, June 9-12, 2011 in London, UK. "Data being presented this week at EHA continue to demonstrate the strength of clinical evidence for carfilzomib, including the final results from the 005...

2011-06-03 12:39:40

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy. Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial...

2011-05-18 07:31:00

SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, and ONX 0912, an oral proteasome inhibitor, in hematological cancers at the 47th American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2011 in Chicago, IL. "The data that will be presented at ASCO continue to support carfilzomib's potential as a new...

2011-04-04 12:00:00

QUEBEC CITY, April 4 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company")  today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102(nd) annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida. Poster #1965: Entitled, "Antitumor activity of novel Akt inhibitor, perifosine in gastric cell lines",Tae Soo Kim, Hyo Song Kim, Bo...

2010-11-01 06:30:00

CALGARY, Nov. 1 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering preclinical research with reovirus (REOLYSIN((R))) is available on the European CanCer Organisation (ECCO) website at www.ecco-org.eu. The research is scheduled to be presented at the 22(nd) EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16(th) - 19(th) 2010. The abstract, entitled...

2010-07-12 14:11:11

Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers...

2010-06-08 08:00:00

EMERYVILLE, Calif., June 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 15th Congress of European Hematology, organized by The European Hematology Association (EHA), June 10-13, 2010 in Barcelona, Spain. Presentations will highlight data from the carfilzomib development program in patients with relapsed and/or refractory multiple...

2010-05-18 12:00:00

MENLO PARK, Calif., May 18 /PRNewswire/ -- A recently completed randomized trial compared three ways to deliver a behavioral smoking cessation program using varenicline (Chantix®): by phone, web, or both. Although phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, no differences in abstinence outcomes were seen at six months. The findings suggest the three programs are all effective treatment options when...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related